Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands

B. A. L. M. Deiman1 · P. A. L. Tonino2 · K. Kouhestani2 · C. E. M. Schröver1 · V. Scharnhorst1 · L. R. C. Dekker2 · N. H. J. Pijls2

Abstract
Aim This study explores clinical outcome in cytochrome P450 2C19 (CYP2C19)-related poor metaboliser patients treated with either clopidogrel or prasugrel after percutaneous coronary intervention (PCI) and investigates whether this could be cost-effective.
Methods and results This single-centre, observational study included 3260 patients scheduled for elective PCI between October 2010 and June 2013 and followed for adverse cardiovascular events until October 2014. Post PCI, CYP2C19 poor metaboliser patients were treated with clopidogrel or prasugrel, in addition to aspirin. In total, 32 poor metabolisers were treated with clopidogrel and 41 with prasugrel. The number of adverse cardiovascular events, defined as death from cardiovascular cause, myocardial infarction, stent thrombosis, every second visit to the catheterisation room for re-PCI in the same artery, or stroke, within 1.5 years of PCI, was significantly higher in the CYP2C19 poor metaboliser group treated with clopidogrel \( n = 10, 31 \% \) compared with the poor metaboliser group treated with prasugrel \( n = 2, 5 \% \) \( (p = 0.003) \). Costs per gained quality-adjusted life years (QALY) were estimated, showing that genotype-guided post-PCI treatment with prasugrel could be cost-effective with less than €10,000 per gained QALY.
Conclusion This study provides evidence that for CYP2C19-related poor metabolisers prasugrel may be more effective than clopidogrel to prevent major adverse cardiovascular events after PCI and this approach could be cost-effective.

Keywords Clopidogrel · Prasugrel · CYP2C19 · Stent thrombosis · Cost-effectiveness

Introduction
Over the last decade, dual antiplatelet therapy with aspirin and clopidogrel has been considered the gold standard therapy for patients undergoing elective percutaneous coronary interventions (PCI) in preventing major adverse cardiovascular events (MACE) [1]. However, resistance to clopidogrel is a well-described phenomenon, with 15–30 % of patients having inadequate platelet inhibition while on therapy [1, 2]. Both clinical factors and genetic polymorphisms are involved in resistance to clopidogrel [2, 3].

Clopidogrel is a pro-drug that requires biotransformation to generate an active metabolite involving cytochrome P450 (CYP) enzymes [4]. It was shown that the CYP2C19 enzyme plays a crucial role in this metabolism [5–7]. Clopidogrel-treated patients carrying at least one reduced-function CYP2C19 allele were shown to have a significantly higher risk for MACE, especially stent thrombosis, than non-carriers [6–9]. These results were confirmed by many studies and two meta-analyses [2, 10, 11]. At the end of 2010 these findings resulted in a Food and Drug Administration (FDA) boxed warning advising healthcare professionals to consider using other antiplatelet medication or alternative dosing strategies for clopidogrel in CYP2C19 poor metaboliser patients.

Therefore, in September 2010 Catharina Hospital started to determine the CYP2C19 genotype of patients sched-
uled for elective PCI in order to identify CYP2C19 poor metabolisers. At first, poor metabolisers were treated with clopidogrel. After the FDA boxed warning was placed, prasugrel was prescribed instead of clopidogrel to the poor metabolisers, with the goal to reduce the number of MACE. In this paper the results of this therapy change are presented. In addition, the cost-effectiveness of genotype-guided post-PCI treatment is discussed.

Methods

Design, setting and definitions

Between September 2010 and June 2013, patients who were scheduled for elective PCI at Catharina Hospital in Eindhoven were enrolled in this study. Patients with ST-segment elevation myocardial infarction (STEMI) who received primary PCI were not included. CYP2C19 genotyping was performed for all patients. Initially, all patients were treated with a start-up dose of clopidogrel (300 mg) and, post-PCI, clopidogrel (75 mg daily) in addition to aspirin (80 mg daily) was prescribed for at least one year. But since the FDA boxed warning, gradually only prasugrel (10 mg daily) instead of clopidogrel was prescribed to CYP2C19 poor metabolisers within 1 to 5 days of PCI, starting in September 2011. Thereby, two groups of CYP2C19 poor metabolisers were studied, one group treated with clopidogrel and another with prasugrel. As stent thrombosis was shown by autopsy to be the cause of death 492 days after PCI for one of the deceased patients in our study, all CYP2C19 poor metabolisers were followed for at least 1.5 years after PCI, the last patient until October 2014. For all CYP2C19 poor metabolisers clinical baseline characteristics were recorded and the medical history was examined for cardiovascular events. An adverse cardiovascular event was defined as death from a cardiovascular cause, myocardial infarction, stent thrombosis, every second visit to the catheterisation room for re-PCI in the same artery, or stroke. Stent thrombosis was defined according to Academic Research Consortium (http://circ.ahajournals.org/content/115/17/2344). For verification of medication prescribed after PCI, the medical file was consulted or the pharmacy or general practitioner was contacted.

Blood sampling, genotyping and phenotyping

Blood for genotyping was obtained during scheduled blood collection immediately before PCI. Genomic DNA was isolated from the patient’s blood using a commercial DNA extraction kit (Roche Diagnostics Inc.) and a semi-automatic extraction device, the Magnapure (Roche). CYP2C19 genotyping was performed with real-time polymerase chain reaction and melting temperature analysis using the Lightcycler hybridisation DNA master mix (Roche Diagnostics Inc.) and specific primers and probes for detection of the CYP2C19*2 and *3 alleles and the *17 allele (TIP-MOL-BIOL and Sigma-proligo) on the Lightcycler 480 (Roche). Based on the genotypes, patients with CYP2C19 wild-type were phenotyped as extensive metabolisers, CYP2C19*2 heterozygote and CYP2C19*3 heterozygote patients as intermediate metabolisers, CYP2C19*2 homozygotes as poor metabolisers and CYP2C19*17 homozygotes as ultra-rapid metabolisers. The CYP2C19*17 heterozygote patients were phenotyped as extensive metabolisers and CYP2C19*2*17 as intermediate metabolisers.

Data analysis

For the baseline characteristics, variables with a Gaussian distribution were presented as mean ± standard deviation. P-values were evaluated by a Chi-squared or Fisher’s exact test using the SPSS statistics software (IBM), version 19 for statistical analyses.

The cost-effectiveness analysis was based on the low-discrimination scenario of Kazi and colleagues[12], including direct medical costs, induced costs, and acute event costs, and in addition to stent thrombosis also cardiovascular death other than stent thrombosis (e.g. bleeding) was included.

Results

CYP2C19 allele frequencies

A total of 3260 patients were enrolled in this study of which 2293 were wild-type, 932 were heterozygotes and 89 homozygotes for the CYP2C19*2 allele. In addition, 6 patients were heterozygotes for the CYP2C19*3 allele, 1121 were heterozygotes for the CYP2C19*17 allele and 175 patients were homozygotes for the CYP2C19*17 allele. This results in allele frequencies of 17, 0.1 and 22.5 % for CYP2C19*2, CYP2C19*3 and CYP2C19*17, respectively, which is in agreement with the allele frequency of a normal Caucasian population [13].

Cardiovascular events

Although all patients were scheduled for PCI, only 71 poor metabolisers (CYP2C19*2 homozygote) (80 %) underwent PCI with stent placement. These 71 poor metabolisers were subdivided based on the antiplatelet drug used. Initially, 32 poor metaboliser patients were treated with clopidogrel, 35 with prasugrel, 2 with ticagrelor and for 2 patients the drug used could not be confirmed (Fig. 1). For 7 patients, 6 using
Advertisement placed here.
Advertisement placed here.
Advertisement placed here.
Advertisement placed here.
clopidogrel and 1 using prasugrel, medication was changed after an additional PCI. Therefore, these patients are part of more than one group. In total, 32 poor metabolisers were enrolled in the clopidogrel group and 41 poor metabolisers in the prasugrel group (Fig. 2). In the clopidogrel group, 19 patients did not have an event, 10 patients had an event within 1.5 years of PCI and for 3 patients this was after more than 1.5 years. In the prasugrel group, 39 patients did not have an event and 2 patients had event within 1.5 years of PCI. No significant difference was observed in the baseline characteristics of the two groups (Table 1). However, the difference in number of events between the clopidogrel and prasugrel group was found to be significant: \( p < 0.001 \) for all events and \( p = 0.003 \) for events within 1.5 years of PCI.

All three events that took place more than 1.5 years post-PCI were diagnosed as chest pain due to in-stent stenosis, which is not related to the patient’s CYP2C19 genotype. Of the 12 events that took place within 1.5 years of PCI, 9 are categorised as MACE (stent thrombosis, myocardial infarction, death), 8 in the clopidogrel group and 1 in the prasugrel group \( (p = 0.008) \) (Table 2). There were 6 cases of stent thrombosis, of which 5 definite and 1 probable. Of the 5 definite stent thromboses, 4 occurred in the clopidogrel group and 1 in the prasugrel group. One patient died of stent thrombosis 492 days after PCI as confirmed by autopsy; however, clopidogrel was no longer prescribed at the time of the event. A myocardial infarction in the coronary artery with the implanted stent 374 days after PCI, while the patient was still using clopidogrel, was defined as probable stent thrombosis. Three people died because of stent thrombosis and one patient died of a probable cardiovascular cause. No major bleeding events were reported for these CYP2C19 poor metabolisers. No events occurred in the ticagrelor group but the number of patients using ticagrelor was too small for comparison and statistical analysis.

**Stent thrombosis**

Among the MACE, the most evidence for an association with CYP2C19-related clopidogrel resistance is shown for stent thrombosis [6, 8–11]. Previously, the increased percentage of stent thrombosis for subjects carrying at least one CYP2C19*2 reduced-function allele compared with non-carriers were reported [6] and the incidence of stent thrombosis was shown to be cumulative according to the number of CYP2C19*2 alleles [8]. Based on these studies, the number of stent thromboses for the Catharina study population in the event that all patients would have been treated with clopidogrel was predicted. For poor metabolisers, the predicted number of stent thromboses was 4 (Table 3), of which 3 are expected to be CYP2C19-related, which is in agreement with the number of stent thromboses found in the present study.

As our results for poor metabolisers are in agreement with the literature, the same is expected to be the case for intermediate and extensive metabolisers. The chance to de-

---

**Fig. 1** Antiplatelet treatment of CYP2C19 poor metabolisers after PCI with stent placement. The number of patients scheduled for elective PCI, phenotyped as CYP2C19 poor metabolisers, and who received a stent is indicated. Patients were subdivided based on the drug used for antiplatelet therapy. For 6 patient using clopidogrel, prasugrel was prescribed after the event, and for one patient treated with prasugrel, ticagrelor was prescribed after the event. PM poor metaboliser, PCI percutaneous coronary intervention

**Fig. 2** Cardiovascular events in the clopidogrel and prasugrel CYP2C19 poor metaboliser group. An event is defined as death, MI, stent thrombosis or angina pectoris with additional intervention in the same coronary artery. The difference in number of events between the clopidogrel and prasugrel group was found to be significant: \( p < 0.001 \) for all events and \( p = 0.003 \) for events within 1.5 years of PCI.
### Table 1  Baseline characteristics of the CYP2C19 poor metabolisers

|                  | Clopidogrel n = 32 | Prasugrel n = 41 | p-value |
|------------------|---------------------|------------------|---------|
| **Age, mean (SD), years** | 65.2 (10.2) | 64.2 (11.1) | 0.680 |
| **Sex, n (%)** |                      |                  |         |
| Male             | 22 (69)             | 30 (73)          | –       |
| Female           | 10 (31)             | 11 (27)          | 0.680   |
| **Race, n (%)** |                      |                  |         |
| Caucasian        | 32 (100)            | 40 (98)          | –       |
| Asian            | 0 (0)               | 1 (2)            | 0.370   |
| **Medical history, n (%)** |                  |                  |         |
| Smoker           | 8 (25)              | 8 (20)           | 0.600   |
| Diabetes mellitus| 7 (22)              | 7 (17)           | 0.630   |
| Hypertension     | 17 (53)             | 14 (34)          | 0.110   |
| Hypercholesterolaemia | 9 (28)         | 16 (39)          | 0.340   |
| Previous PCI     | 14 (44)             | 17 (41)          | 0.750   |
| Previous MI      | 14 (44)             | 22 (54)          | 0.420   |
| Previous CABG    | 7 (22)              | 13 (32)          | 0.350   |
| **Pharmacotherapy, n (%)** |                  |                  |         |
| Beta-blocker     | 23 (72)             | 34 (83)          | 0.260   |
| ACE inhibitor    | 7 (22)              | 13 (32)          | 0.350   |

*CABG* coronary artery bypass graft, *MI* myocardial infarction, *PCI* percutaneous intervention

### Table 2  Events in poor metabolisers within 18 months of PCI

|                  | Clopidogrel n = 32 (days after PCI) | Prasugrel n = 41 (days after PCI) | Death | Info |
|------------------|--------------------------------------|-----------------------------------|-------|------|
| **Myocardial infarction** | 46 days | – | No | – |
|                  | 412 days | – | No | – |
| **Stent thrombosis**<sup>a</sup> | – | 2 days | Yes | – |
|                  | 4 days | – | No | – |
|                  | 4 days | – | Yes | – |
|                  | 7 days | – | No | – |
|                  | 492 days | – | Yes | Autopsy |
| **Stent thrombosis probable**<sup>a</sup> | 374 days | – | No | – |
| **Angina pectoris**<sup>b</sup> | – | 451 days | No | – |
|                  | 70 days | – | No | – |
|                  | 158 days | – | No | – |
| **Unknown** | 112 days | – | Yes | – |
| **Total number of events** | 10 | 2 | – | – |

<sup>a</sup>According to the American Research Consortium Statement

<sup>b</sup>Including an additional intervention in same coronary artery

### Table 3  Predicted number of stent thromboses

| Patient CYP2C19 phenotype | Stent thrombosis | CYP2C19-independent | CYP2C19-related |
|---------------------------|-------------------|----------------------|-----------------|
| Number                    | Chance<sup>a</sup> | Number   |      |     |
| EM/UM                     | 2239              | 0.008     | 18   | 18  |
| IM                        | 932               | 0.026     | 24   | 7   |
| PM                        | 89                | 0.043     | 4    | 1   |
| **Total**                 | 3260              | –         | **46** | 20 |
|                           | 1.41 %            |          | 0.61 % |

<sup>a</sup>Based on the percentages of stent thrombosis for subjects carrying at least one CYP2C19*2 allele compared with non-carriers (2.7 % vs. 0.8, respectively) as described by Mega and colleagues [6], and the cumulative incidence of stent thrombosis according to the number of CYP2C19*2 alleles [8]. In case of CYP2C19 independence it is assumed that the chances for poor metabolisers (PM) and intermediate metabolisers (IM) are identical to that of extensive metabolisers (EM). The total number of stent thrombosis minus the CYP2C19-independent stent thrombosis is predicted to be the number of CYP2C19-related stent thrombosis
velop stent thrombosis for intermediate metabolisers is considerably lower than for poor metabolisers (2.6 % vs. 4.3 %, respectively), but still higher than for extensive metaboliser or ultra-rapid metaboliser patients (0.8 %) (Table 3). Because of the large group of intermediate metabolisers this is predicted to result in 24 additional cases of stent thrombosis of which 17 are CYP2C19-related (Table 3).

Cost-effectiveness

In addition to clopidogrel, prasugrel and ticagrelor can be used to reduce the rate of thrombotic cardiovascular events for patients who undergo PCI [14–16] and are even recommended for most patients with acute coronary syndromes (ACS) [17, 18]. CYP2C19 is involved in the metabolism of prasugrel, but it does not play a crucial role [2, 5]. Ticagrelor is a direct drug and its metabolism is independent of CYP2C19 activity. However, both agents are much more expensive than clopidogrel and in most countries these agents are only reimbursed for ACS.

Based on the latest prices for clopidogrel, prasugrel and ticagrelor, approximately € 25, € 720 and € 866 per year, respectively, according to the National Health Care Institute (Zorginstituut Nederland, https://www.medicijnkosten.nl/), the pharmaceutical expenses for six different therapy options for the Catharina study population were compared (Table 4). Giving prasugrel to all patients would mean a high increase in pharmaceutical expenses of approximately € 2,200,000 compared with clopidogrel. A less expensive alternative is to give prasugrel only to the high-risk poor metabolisers. This increases the pharmaceutical expenses by just € 60,000, but genotyping is required, resulting in an additional € 270,500 (€ 83 per test according to the latest tariffs of the Dutch Healthcare Authority (NZA)). As intermediate metabolisers also have an increased risk for MACE while on clopidogrel therapy [10], both the intermediate and poor metabolisers could be treated with prasugrel, preventing all the CYP2C19-related events (Table 3). This leads to an increase in pharmaceutical expenses of over € 700,000 and additional costs for genotyping. Because of the higher drug price, these numbers are even higher for both the ticagrelor therapy options (Table 4).

Recently, the results of a cost-effectiveness study of genotype-guided dual antiplatelet therapies for ACS in the United States were presented [12]. It was concluded that treatment with prasugrel or ticagrelor for all patients was relatively expensive, but both genotype-guided therapy with prasugrel or ticagrelor may be an economically reasonable alternative for clopidogrel in dual antiplatelet therapy. The incremental quality-adjusted life years (QALYs) as presented by Kazi and colleagues [12] were used to calculate the gained QALYs for the different therapy options presented above. As expected, the costs per gained QALY for prasugrel for all patients is high, € 38,611 per gained QALY (Table 3). But, for genotype-guided prasugrel and genotype-guided ticagrelor, these costs per gained QALY are much lower, € 9111 and € 5972, respectively. In addition, the gained QALY for ticagrelor for all patients

| Table 4 | Cost and QALY |
|---------|--------------|
| CYP2C19 phenotype | Patient number | Clopidogrel | Prasugrel | Prasugrel PM | Prasugrel PM + IM | Ticagrelor PM | Ticagrelor |
| EM or UM | 2239 | € 55,975 | € 1,612,080 | € 55,975 | € 55,975 | € 55,975 | € 1,938,974 |
| IM | 932 | € 23,300 | € 671,040 | € 23,300 | € 671,040 | € 807,112 | € 807,112 |
| PM | 89 | € 2225 | € 64,080 | € 64,080 | € 64,080 | € 77,074 | € 77,074 |
| Total pharmaceutical costs | | € 81,500 | | € 2,347,200 | € 143,355 | € 791,095 | € 940,161 | € 2,823,160 |
| Difference PC | | € 2,265,700 | € 61,855 | € 709,595 | € 858,661 | € 2,741,660 |
| Costs genotyping (€ 83/test) | | € 0 | € 270,580 | € 270,580 | € 270,580 | € 0 |
| Extra costs | | € 2,265,700 | € 332,435 | € 980,175 | € 1,129,241 | € 2,741,660 |
| Incremental QALY | 0.018 | nd | 0.033 | 0.058 | 0.105 |
| Gained QALY | 58.68 | 33.95 | 107.58 | 189.08 | 342.3 |
| Extra cost/gained QALY | € 38,611 | € 9792 | € 9111 | € 5972 | € 8010 |

Clopidogrel: € 25/year, prasugrel: € 720/year, ticagrelor: € 855/year
PM poor metaboliser, IM intermediate metaboliser, EM extensive metaboliser, UM ultra-rapid metaboliser, nd not determined, PC pharmaceutical costs, QALY quality-adjusted life year, ST stent thrombosis

aAccording to Kazi and colleagues [12]

bGained QALY = incremental QALY x number of patients of study population (n = 3260)

cThis option was not determined by Kazi and colleagues; therefore, the gained QALYs were calculated based on the 8 cases of MACE reported in Table 2 and the estimation that patients aged 65 years having PCI for ACS and being treated with clopidogrel and aspirin for 12 months are projected to have a life expectancy of 9.428 QALYs over their lifetimes [12]. Three patients could have been prevented from dying, which equals 28.3 QALYs. For the 5 patients who did survive stent thrombosis or myocardial infarction a 12 % permanent quality-of-life decrement is assumed [12], which equals 5.66 QALYs. Together, it is estimated that 33.95 QALYs could have been gained.
is also low at € 8010 per gained QALY. This difference in incremental cost-effectiveness ratio between prasugrel and ticagrelor was previously explained by the increase of fatal bleeding when using prasugrel [12, 14, 15]. The costs per gained QALY for prasugrel for poor metaboliser patients only, as routinely applied in Catharina Hospital, were estimated to be € 9792.

Discussion

In this study, based on real-world observations among 3260 elective PCI patients, we found an increased risk for cardiovascular events in CYP2C19 poor metabolisers treated with clopidogrel compared with prasugrel. These results support that CYP2C19 poor metaboliser patients are considered to be at high risk for recurrent events if treated with clopidogrel, as previously described [6, 8–11].

In the Netherlands, the mean ‘willingness to pay’ is estimated to be about € 65,000 per QALY based on the Dutch EQ-5D tariffs and visual analogue scale valuations [19, 20]. Our analysis shows that prasugrel for poor metaboliser patients only, as routinely applied in the Catharina Hospital, could be cost-effective. In addition, it is implementable in daily clinical practice, with relatively low additional costs, and, in the Netherlands, prasugrel in combination with acetylsalicylic acid is approved and reimbursed when prescribed after stent placement, also in case of non-ACS (https://www.medicijnkosten.nl/).

In addition to the high-risk CYP2C19 poor metaboliser patients, also the intermediate metabolisers are at increased risk for MACE [10]. Following the USA [12], our cost-effectiveness analysis shows that also in the Netherlands, the genotype-guided prasugrel and genotype-guided ticagrelor therapy for both CYP2C19 poor metaboliser and intermediate metaboliser patients, and even ticagrelor for all patients could be economically reasonable alternatives for clopidogrel therapy. These results could help in political discussions and discussions with health insurance companies, which may result in changing daily clinical practice to genotype-guided antiplatelet therapy in future.

Limitations

Although being in line with the literature [6, 8], the number of events is too small to draw any definite conclusions, emphasising the need for further studies to confirm the present results. Baseline characteristics were comparable between the clopidogrel and prasugrel group, but the observational design of the study cannot fully correct for other sources of bias that may have influenced the results. The switch from clopidogrel to prasugrel took place within 1 to 5 days of PCI; however, it is unclear if more events could have been prevented if prasugrel had been given to the poor metabolisers on the day of PCI. Also, it cannot be excluded that the use of ‘second-generation stents’ could have influenced the results [21].

Conclusion

This study provides evidence that for CYP2C19-related poor metabolisers prasugrel may be more effective than clopidogrel to prevent major adverse cardiovascular events after PCI and this approach could be cost-effective.

Funding None

Conflict of interest B.A.L.M. Deiman, P.A.L. Tonino, K. Kouhestani, C.E.M. Schrover, V. Scharnhorst, L.R.C. Dekker and N.H.J. Pijls state that they have no competing interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Garabedian T, Alam S. High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther. 2013;3:23–37.
2. Oprea AD, Popescu WM. P2Y12 receptor inhibitors in acute coronary syndromes: what is new on the horizon? Cardiol Res Pract. 2013;2013:195456. doi:10.1155/2013/195456.
3. Cusset T, Morange PE, Alessi MC. Recent advances in the pharmacogenetics of clopidogrel. Hum Genet. 2012;131:653–64.
4. Beitelshees AL, Horenstein RB, Vesely MR, Mehra MR, Shuldiner AR. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. Clin Pharmacol Ther. 2011;89:455–9.
5. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429–36.
6. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119:2553–60.
7. Shuldiner AR, O’Connell JR, Belden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–57.
8. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30:916–22.
9. Cayla G, Hulot JS, O’Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;30:1765–74.
10. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821–30.
11. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 2011;11:199–206.
12. Kazi DS, Garber AM, Shah RU, et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med. 2014;160:221–32.
13. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94:317–23.
14. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.
15. Cuisset T, Loosveld M, Morange PE, et al. CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc Interv. 2012;5:1280–7.
16. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320–8.
17. Yetgin T, van der Linden MM, de Vries AG, et al. CCR Study Investigators. Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes. Neth Heart J. 2014;22:55–61. doi:10.1007/s12471-013-0472-1.
18. Vos GJ, Bennaghmouch N, Qaderdan K, Ten Berg JM. Management of the patient with an acute coronary syndrome using oral anticoagulation. Neth Heart J. 2015;23:407–14. doi:10.1007/s12471-015-0727-0.
19. Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health. 2010;13:1046–55.
20. Obradovic M. Searching for the social value of a QALY in the Netherlands: the willingness to pay for a QALY. Master thesis health economics. Rotterdam: Erasmus University Rotterdam; 2012.
21. Felix C, Everaert B, Diletti R, et al. Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. Neth Heart J. 2015;23:153–60. doi:10.1007/s12471-015-0652-2.